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Although the presence of an olfactory impairment in Parkinson’s
disease (PD) has been recognized for 25 years, its cause remains
unclear. Here we suggest a contributing factor to this impairment,
namely, that PD impairs active sniffing of odorants. We tested 10
men and 10 women with clinically typical PD, and 20 age- and
gender-matched healthy controls, in four olfactory tasks: (i) the
University of Pennsylvania smell identification test; (ii and iii)
detection threshold tests for the odorants vanillin and propionic
acid; and (iv) a two-alternative forced-choice detection paradigm
during which sniff parameters (airflow peak rate, mean rate,
volume, and duration) were recorded with a pneomatotacho-
graph-coupled spirometer. An additional experiment tested the
effect of intentionally increasing sniff vigor on olfactory perfor-
mance in 20 additional patients. PD patients were significantly
impaired in olfactory identification (P < 0.0001) and detection (P <
0.007). As predicted, PD patients were also significantly impaired at
sniffing, demonstrating significantly reduced sniff airflow rate (P <
0.01) and volume (P < 0.002). Furthermore, a patient’s ability to
sniff predicted his or her performance on olfactory tasks, i.e., the
more poorly patients sniffed, the worse their performance on
olfaction tests (P < 0.009). Finally, increasing sniff vigor improved
olfactory performance in those patients whose baseline perfor-
mance had been poorest (P < 0.05). These findings implicate a
sniffing impairment as a component of the olfactory impairment in
PD and further depict sniffing as an important component of
human olfaction.
Parkinson’s disease (PD) is a neurodegenerative disordercharacterized pathologically by progressive neuronal loss,
particularly of aminergic brainstem neurons. PD primarily af-
fects motor control, but it also affects cognitive and sensory
processing (1). Of the sensory impairments associated with PD,
olfactory impairment has received most attention. PD patients
exhibit impairments in odor detection, identification, and dis-
crimination (2–6) and a reduced olfactory evoked response (7,
8). This occurs so consistently that the olfactory impairment may
have diagnostic value for PD (9–12). Although the presence of
an olfactory impairment in PD has been acknowledged for 25
years (2), its cause remains unknown.
Olfaction requires complex sensory–motor integration (13).
Sniffing, the motor component of olfaction, involves transpor-
tation of airborne stimuli to the olfactory receptors. Smelling,
the sensory component of olfaction, involves transduction of
odorants into a neural signal and further processing of that
neural signal. The olfactory impairment in PD has always been
attributed to pathology in the neural substrates of smelling (2–4),
consisting of depletion of neurotransmitters, and the postmor-
tem finding of Lewy bodies, the pathologic hallmark of PD,
throughout the olfactory cortex (9, 15). Here we suggest that
what had long been considered a smelling impairment in PD is
actually, in part, a sniffing impairment. To address this sugges-
tion, we compared the dissociable abilities of sniffing and
smelling in PD patients with those of healthy matched controls.
Methods
Subjects. We tested 10 men and 10 women with clinically typical
idiopathic PD and 20 age- and gender-matched healthy controls.
Subjects diagnosed as potentially atypical PD were excluded.
The patients were mostly stage II on the Hoehn and Yahr staging
of PD (mean 5 2.3, SD 5 0.65), with a mean disease duration
of 8.1 years (SD 5 4.3). All patients were taking dopaminergic
replacement medication and were tested in the ‘‘on’’ condition
(i.e., typically in the middle of the time window between drug
administrations). There were no differences between patients
and controls in age [PD mean 5 67.1, SD 5 9.9; control mean 5
68, SD 5 7.6, t(38)5 0.32, P 5 0.75], in cognitive state as assessed
by the Mini Mental State Examination [PD mean 5 28.1, SD 5
1.9; control mean 5 28.75, SD 5 2, t(38) 5 0.99, P 5 0.33], in
years of formal education [PD mean 5 15.8, SD 5 3; control
mean 5 16.9, SD 5 2.7, t(38) 5 1.1, P 5 0.27], in handedness
(PD 5 18R, 2L; control 5 17R, 3L), or in smoking behavior
(none of the patients or controls was a current smoker; nine of
the patients and 10 of the controls had smoked in the past).
Patients’ scores on the unified Parkinson’s disease rating scale
(UPDRS) were as follows: part I (mentation behavior and
mood), mean 5 2.4, SD 5 2.1; part II (activities of daily living),
mean 5 11.9, SD 5 5.2; part III (motor examination), mean 5
18.7, SD 5 12.4 (UPDRS scores were not obtained for one of the
20 patients).
Smell Identification. All subjects performed the University of
Pennsylvania smell identification test (UPSIT). This test consists
of 40 scratch-and-sniff presentations of odorants in a four-
alternative forced-choice identification paradigm. The UPSIT is
widely used in clinical and experimental settings and enables
comparison to published standardized scores based on large
normative data sets (16). To reduce potential sources of vari-
ance, rather than permitting self-administration, the UPSIT was
administered to the subjects (both PD and control) by the
experimenters. The odorant was scratched by the experimenter
and then held to the subject’s nose for smelling. Because PD
patients may display specific anosmias (17), the order of UPSIT
stimulus presentation was randomized and balanced across
subjects.
Smell Detection Threshold. Detection thresholds for the odorants
vanillin and propionic acid were tested in all subjects. These
odorants were chosen so as to target both the olfactory (vanillin)
and trigeminal (propionic) systems (18, 19). Dilution series of
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the odorants were prepared in double-distilled di-ionized water.
Pairs consisting of an odorant and a diluent were then presented
to blindfolded subjects in a randomized two-alternative forced-
choice ascending staircase procedure (20), with five consecutive
hits as criteria for threshold.
Airflow. Sniff parameters were recorded during a two-alternative
forced-choice detection paradigm with methods described in
refs. 22 and 27 (Fig. 1). Subjects were presented with a nose mask
(Respronics, Murrysville, PA) coupled to an odorant source and
a pneomatotachograph that relayed changes in pressure to an
amplifier (spirometer; A. D. Instruments, Milford, MA). The
transduced signal was displayed and recorded on a computer.
Measures of airf low rate, duration, and volume were extracted
with commercially available software designed specifically for
these measures (CHART 3.6.3 with SPIROMETRY extension; A. D.
Instruments). The test consisted of 24 odorant presentations: 12
no-odorant trials randomly interspersed with 12 suprathreshold
vanillin trials (four low concentration, four intermediate con-
centration, and four high concentration). In a later described
control experiment, we also measured sniffing during the UPSIT
before and after a manipulation that consisted of verbally
instructing patients to increase their sniff vigor. In this control,
the odorant source was cut out of the UPSIT and placed within
the nose mask. UPSIT stimuli were randomized and balanced
between the pre- and postmanipulation batch, across subjects. In
all experiments, subjects were unaware that airf low was being
measured.
Finger Tapping. As an additional measure of motor performance,
each subject used the index finger to tap on a counter as many
times as possible within 10 s. The task was repeated four times,
twice with each hand. The score was the mean of the four
performances.
Results
PD patients were impaired on all measures of olfaction (Fig. 2).
Two-tailed unpaired t tests revealed significantly reduced UPSIT
performance for patients (mean 5 21.2, SD 5 6.7) compared
with controls (mean 5 32.8, SD 5 4.3) [t(38) 5 6.52, P , 0.0001],
significantly reduced vanillin detection for patients (mean 5 9.3,
SD 5 3.7) compared with controls (mean 5 5.9, SD 5 3.8)
[t(38) 5 2.86, P 5 0.007], and significantly reduced propionic
acid detection for patients (mean 5 8, SD 5 2.7) compared with
controls (mean 5 5.2, SD 5 2.8) [t(38) 5 3.2, P 5 0.003]. The
PD deteriorations in vanillin detection and propionic acid
detection were similar [F(1,38) 5 0.25, P 5 0.62].
PD patients were impaired at sniffing (Fig. 3). Two-tailed
unpaired t tests revealed significantly reduced values in patients
compared with controls in sniff peak airf low rate [PD mean 5
0.25 literys, SD 5 0.08; control mean 5 0.31 literys, SD 5 0.08,
t(38) 5 2.6, P 5 0.01], sniff mean airf low rate [PD mean 5 0.16
literys, SD 5 0.05; control mean 5 0.21 literys, SD 5 0.05,
t(38) 5 3.6, P 5 0.0009], sniff volume [PD mean 5 0.3 liter, SD 5
0.13; control mean 5 0.44 liter, SD 5 0.14, t(38) 5 3.38, P 5
0.0017], and bout volume [PD mean 5 0.43 liter, SD 5 0.14;
control mean 5 0.56 liter, SD 5 0.13, t(38) 5 3.042, P 5 0.0042].
There were no significant differences in sniff duration [PD
mean 5 1.9 s, SD 5 0.9; control mean 5 2.16 s, SD 5 0.73,
t(38) 5 0.66, P 5 0.51] or number of sniffs in bout [PD mean 5
1.8, SD 5 0.73; control mean 5 1.6, SD 5 0.48, t(38) 5 1.59, P 5
Fig. 1. Methods for recording airflow. A schematic drawing and image of the recording apparatus as used in refs. 22 and 27 (note the three additional
interchangeable odorant sources at the table). Subjects were told that the tubes connected to the mask were the odorant supply (they were in fact the pressure
transduction tubes). Subsequent questioning revealed that no subject was aware of the ongoing airflow recording. The data in the upper right quadrant is the
actual mean first sniff of 20 patients and 20 controls (the person demonstrating the apparatus is not a patient).









0.12]. The foregoing analysis of sniffing considered only the 12
sniffs from the randomly interspersed no-odorant trials, and not
the 12 sniffs from the odorant trials, because the presence of an
odorant will alter a sniff in a predicted manner (the higher the
odorant concentration, the shorter the sniff) (21, 22). In the
no-odorant trials, sniffs constitute an olfactory search that is
unaffected by odorant presence, i.e., the sniffing component of
olfaction is unaffected by the smelling component. When anal-
ysis was made of all sniffs, however, PD patients exhibited an
identical pattern of impairment.
Thus, PD patients displayed reduced sniffing capabilities in
comparison with healthy controls in the context of an olfactory
task. The absence of significant differences between controls and
patients in sniff duration and number of sniffs per bout indicates
that the patients were trying to perform the task. The PD deficit
in sniff parameters, therefore, is not a reflection of reduced
patient effort at participation.
Among sniff parameters, sniff volume has been determined as
most important for maximizing olfactory performance (21). To
determine whether sniffing capability was related to olfactory
performance within the PD patients, we examined the relation
between sniff volume and olfactory performance as measured
with the UPSIT. There was a significant correlation between
these measures (r 5 0.56, P 5 0.009), such that greater sniff
volume predicted better performance on the separately con-
ducted UPSIT in PD patients. In other words, patients with
greater sniff volume performed better at olfaction; patients with
lesser sniff volume performed worse at olfaction (Fig. 4a).
Because a sniff is in part a motor action, this finding may be
taken to suggest a motor component in the olfactory impairment
in PD. Previous work, however, had suggested that the olfactory
impairment in PD is unrelated to the extent of motor deterio-
ration as assessed by finger tapping (16). This apparent contra-
diction between our finding and previous work by others may be
resolved if the PD-related deterioration in finger tapping were
dissociated from the PD-related deterioration in sniffing. To
address this possibility we compared finger tapping with sniffing
in all patients. There was no correlation between any of the sniff
components and finger tapping (correlations between finger
tapping and sniff parameters: peak airf low rate, r 5 0.23, P 5
0.32; mean airf low rate, r 5 0.27, P 5 0.25; volume, r 5 0.02, P 5
0.9; duration, r 5 0.1, P 5 0.66; bout volume, r 5 0.08, P 5 0.72;
number sniffs in bout, r 5 0.01, P 5 0.9). Finger tapping was not
correlated with olfactory performance (r 5 0.06, P 5 0.9) (Fig.
4b). Furthermore, olfactory performance was not correlated
with the UPDRS motor score (r 5 0.39, P 5 0.12) (Fig. 4c). Only
the subset of questions in UPDRS part III that probe axial rather
than proximal function (questions 1, 2, 3 face 1 lips 1 chin, 5
neck) were significantly correlated with olfactory performance
(r 5 0.50, P 5 0.02) (Fig. 4d) and tended toward a correlation
with sniff volume (r 5 0.42, P 5 0.07).
Effect of Manipulating Sniffing in PD Patients. The above findings
suggest that weaker sniffing is predictive of poorer olfactory
performance in PD. Next, we sought to determine whether an
improvement in sniffing could improve olfactory performance in
PD patients. An additional 20 PD patients (16 men, four women)
were tested in a control experiment where sniff airf low param-
eters were measured while the UPSIT was performed. For each
patient, we divided the UPSIT into two 20-trial sessions. After
the first 20 trials were completed, we then verbally asked the
patient to increase his or her sniff volume during the second
20-trial session. Because visual feedback can assist PD patients
in the coordination of movement (23), we allowed each patient
to take a few sniffs while he or she saw visual feedback
representing their sniff on the computer monitor. UPSIT odor-
ants were randomized and balanced across subjects and sessions.
Our aim was to test (i) whether patients could increase sniff
volume and (ii) whether PD patients could improve olfactory
performance by increasing sniff volume. Of the 20 patients, 18
increased sniff volume. Mean volume increased from 0.29 liter
(SD 5 0.16) to 0.445 liter (SD 5 0.2) [t(19), 5 3.8, P 5 0.001],
a value virtually identical to that in healthy controls (0.444 liter).
Overall, increasing sniff volume led to only a small and insig-
nificant improvement in UPSIT scores, from a mean of 9 of 20
before the sniff increase manipulation to a mean of 10 of 20 after
the manipulation. There appeared, however, to be a bimodal
distribution of patients. Patients who had performed worse at
baseline improved, but those who performed best at baseline did
not improve. To address the possibility of bimodal distribution,
we conducted a median split. The median score at baseline was
7.5 of 20. The 10 patients who scored below the median at
baseline had a significant improvement in olfactory perfor-
mance, from a mean of 5.7 of 20 at baseline to a mean of 8.1 after
sniff volume increase [t(9) 5 2.27, P 5 0.049] (Fig. 5). Two
concerns may be raised regarding this analysis. First, improve-
ment from the first to the second half of the UPSIT could have
occurred as a result of practice, regardless of the sniff improve-
ment manipulation. To address this concern, we compared the
Fig. 2. Olfaction in patients and controls. Patients performed worse than
controls in all olfactory tasks. (a) Relative to the controls, who performed
within the range of published norms (16), patients’ performance on the UPSIT
was near anosmia (complete olfactory loss). The detection threshold scores
achieved represent the following concentrations. (b) For vanillin, controls 5
1.09 3 1024 M in H2O, patients 5 1.13 3 1023 M in H2O. (c) For propionic acid,
controls 5 5.27 3 1024 M in H2O, patients 5 3.8 3 1023 M in H2O. As previously
shown (16), olfactory performance was not significantly correlated in patients
with finger tapping, age, disease duration, cognitive state (Mini Mental State
Examination), or stage of disease progression (Hoehn and Yahr scale).
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first and second halves of the UPSIT scores previously obtained
from 20 patients. In these UPSIT tests, patients in fact per-
formed slightly worse in the second compared with the first half
of the UPSIT, presumably because of fatigue [mean first half 5
11, SD 5 3.9; mean second half 5 10.2, SD 5 2.9, t(19) 5 2, P 5
0.056]. This negates the concern regarding a practice effect.
Second, the improvement seen in the worst performers (at
baseline) could have represented regression toward the mean.
To address this concern, we conducted a median split of the
initial 20 patients. In contrast to the patients in the group with
increased sniff volume, the worst of those performers at baseline
did not improve from the first to the second half of the UPSIT
[mean first half 5 8, SD 5 1.7; mean second half 5 8.2, SD 5
1.6, t(9) 5 0.48, P 5 0.64]. Thus these analyses indicate that the
improvement was related to the sniff volume increase manipu-
lation and did not occur otherwise. The improvement, however,
still left patients at a level of performance far below that of
healthy controls.
Discussion
Here we have shown that sniffing is impaired in PD. The
importance of sniffing as a component of human olfaction has
been suggested in psychophysical, physiological, and imaging
studies. These studies have shown that sniffs not only (i)
transport the stimulus, but also (ii) affect patterns of neural
activity at all levels of the olfactory system (24–26), (iii) are
modulated to account for different odorant concentrations (21,
22, 27), (iv), affect the type of odorant that is perceived (28), and
(v) are a fundamental component of the olfactory percept (21,
22, 26–32). None of these studies, however, had addressed the
consequence of a neurally based impairment in sniffing for
olfactory processing. Here we have addressed this issue in a
neurodegenerative disease and have shown that (i) PD patients
are impaired at sniffing, (ii) sniffing capability predicts olfactory
capability within patients, and (iii) in the worst performers
among the patients, increasing sniff volume improved olfactory
performance. These findings point to an essential role for
sniffing in human olfaction and combine to offer an alternative
explanation for the olfactory deficit in PD.
A key finding was the correlation between sniffing capability
and olfactory performance in PD (Fig. 4a). One may raise the
concern, however, that this correlation did not imply causation.
This concern was largely negated by the continuation study
where improving sniffing improved olfactory performance, sug-
gesting a causal link between poor sniffing and poor olfaction in
PD. Furthermore, PD patients had detection thresholds for the
pure olfactant vanillin, and the strong trigeminal propionic acid
equally deteriorated. If the source of the deficit was in the
olfactory system alone, one might expect a greater impairment
in vanillin than in propionic acid detection. That they were
equally impaired suggests a deficit in a common processing
phase. Sniffing is one such common mechanism subserving
perception of both of these odorants. In turn, in contrast to the
robust sniff impairment finding of this study, the sniff improve-
Fig. 3. Sniffing in patients and controls. Patients displayed significantly reduced sniff airflow (a) peak rate, (b) mean rate, (c) volume, and (d) overall bout
volume. There was no difference between patients and controls in (e) sniff duration and ( f) number of sniffs attempted in a bout before making a decision.
Sniffing performance was not significantly correlated in patients with finger tapping, age, disease duration, cognitive state (Mini Mental State Examination),
or stage of disease progression (Hoehn and Yahr scale).









ment effect was not as extremely robust. Only a slight but
significant improvement in performance was evident in the worst
of performers. Thus a noncausal link between the sniffing
impairment we have shown and the olfactory impairment in PD
remains plausible.
Our findings do not suggest that the sniff impairment is the
sole cause of the olfactory impairment in PD. Increasing sniff
volume only helped the worst of the performers and did not bring
them to normal performance. The remaining nonsniffing com-
ponent of the olfactory impairment is most likely a smelling
impairment related to the disease-induced damage found in the
neural substrates of the olfactory system (9, 15). This neural
damage may be the result of pathological Parkinsonian processes
unrelated to sniffing. Alternatively, this damage in itself may be
the result of altered sniffing. The olfactory system is highly
sensitive to sensory deprivation. For example, in rats, merely
reducing airf low in a nostril results in extensive damage and
deterioration throughout the olfactory system (33, 34). Thus, the
sniffing impairment in PD may constitute a form of olfactory
deprivation that in turn leads to degradation throughout the
olfactory system. In this manner, the sniffing impairment may
not only be a component of the eventual olfactory impairment,
but also potentially the cause of the nonsniffing components in
this impairment. The latter is merely our speculation regarding
the significance of the sniff impairment documented here. This
speculation, however, is significant in that it suggests a reversal
in the current concept of cause and effect in the formation of the
typical Parkinsonian lesions throughout olfactory cortex.
Fig. 4. Predictors of olfactory performance in PD. (a) Better sniffing predicted better olfactory performance in PD. (b) Motor performance as assessed by finger
tapping did not significantly predict olfactory performance in PD. (c) Motor performance as assessed by a standard test (UPDRS part III) did not significantly predict
olfactory performance in PD. (d) A subset of the UPDRS part III, representing only axial function, significantly predicted olfactory performance in PD (note that
one subject had a significantly outlying UPDRS score and is therefore not depicted in the scattergram. Graph c remained insignificant, and d remained significant,
with or without this subject).
Fig. 5. Effects of increasing sniff volume on olfactory performance. (a) Increases in sniff volume from spontaneous sniffing (Pre) to sniffing after instructions
(Post), in the 10 worst olfactory performing patients. (b) Improvement in olfactory performance between baseline (Pre) and after sniff volume increases (Post)
in the same 10 worst olfactory performing patients. Increasing sniff volume led to a significant improvement in performance.
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The sniffing impairment did not appear to be a simple
extension of the generalized motor impairment in PD. Neither
sniffing nor olfactory performance was significantly correlated
with either the UPDRS motor scale or finger tapping ability.
Furthermore, 18 of the 20 patients were able to increase their
sniff volume upon request. In other words, most PD patients
were able to sniff more than they did spontaneously. In fact,
patients increased sniff volume by 72%, bringing their sniff
volume to a value almost identical to that of controls (0.444 liter
in controls and 0.445 liter in improved patients). Thus, whereas
in healthy individuals a sniff was an automatic implicit response,
in PD patients a sniff was a cue-dependent explicit response. This
pattern is in agreement with the deficiency in internal triggering
and cueing of movement sequences (35) and hampered timing of
sensory acquisition motor sequences (36) associated with PD.
Therefore, rather than ‘‘motor impairment’’ per se, we propose
that the sniff impairment represents an impairment in the
coordination of sensory, attentional, and motor mechanisms that
combine to produce a sniff. That said, olfactory performance
was significantly correlated with an axial subset of the UPDRS
motor scale (i.e., motor measures related to the torso, head, and
neck, and not arms and legs), leaving the possibility that the
sniffing impairment in PD is but another purely motor symptom
of PD.
Finally, although the improvement in olfactory performance
witnessed in this study was small, this effect was nevertheless
striking, as it is unusual that a simple behavioral suggestion
partially ameliorates a sensory impairment induced by a long-
term neurodegenerative disease. This amelioration is important,
considering the implications of reductions in olfactory sensitivity
(termed anosmia) on quality of life. Anosmia can alter food
choices and intake, resulting in impaired nutritional status,
challenged immunity, and weight loss (37, 38). Anosmia may also
deprive patients of a valuable warning mechanism for life
hazards, such as smoke, gas, spoiled food, and chemical con-
taminations (39). Last but not least, anosmia deprives patients of
the hedonic pleasures related to good food and wine, as well as
the pleasures related to the smell of a new car, a flower, or a
loved one. Our findings, combined with previous anecdotal
olfactory improvements reported in two PD patients (14), sug-
gest that this loss may be at least partially reversed.
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